Fagret D - Search Results

1

Potential use of radiolabeled antisense oligonucleotides in oncology.

Gauchez AS, Du Moulinet D'Hardemare A, Lunardi J, Vuillez JP, Fagret D. Gauchez AS, et al. Among authors: fagret d. Anticancer Res. 1999 Nov-Dec;19(6B):4989-97. Anticancer Res. 1999. PMID: 10697501 Review.

2

Early detection of chemoresistance in vivo through the use of a radiolabeled antisense oligonucleotide.

Touboul M, Gauchez AS, D'Hardemare Adu M, Lunardi J, Deverre JR, Pernin C, Mathieu JP, Vuillez JP, Fagret D. Touboul M, et al. Among authors: fagret d, d hardemare adu m. Anticancer Res. 2002 Nov-Dec;22(6A):3349-56. Anticancer Res. 2002. PMID: 12530086

3

Prospect for anti-HER2 receptor therapy in breast cancer.

Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. Brand FX, et al. Among authors: fagret d. Anticancer Res. 2006 Jan-Feb;26(1B):463-70. Anticancer Res. 2006. PMID: 16739306 Free article. Review.

4

Prospect for anti-her2 receptor therapy in breast cancer.

Brand FX, Ravanel N, Gauchez AS, Pasquier D, Payan R, Fagret D, Mousseau M. Brand FX, et al. Among authors: fagret d. Anticancer Res. 2006 Jan-Feb;26(1B):715-22. Anticancer Res. 2006. PMID: 16739343 Free article. Review.

5

Detection of chemoresistance profile of cell lines K562, KB, GLC4 and HL60 through characterisation of the hmdr1, mrp and lrp transcripts.

Gauchez AS, Lunardi J, Pernin C, Marti-Battle D, Fagret D. Gauchez AS, et al. Among authors: fagret d. In Vivo. 2001 Jan-Feb;15(1):101-4. In Vivo. 2001. PMID: 11286118

6

First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.

Rebischung C, Hoffmann D, Stefani L, Desruet MD, Wang K, Adelstein SJ, Artignan X, Vincent F, Gauchez AS, Zhang H, Fagret D, Vuillez J, Kassis AI, Balosso J. Rebischung C, et al. Among authors: fagret d. Int J Radiat Biol. 2008 Dec;84(12):1123-9. doi: 10.1080/09553000802395535. Int J Radiat Biol. 2008. PMID: 19061137

7

Targeted radionuclide therapy with RAFT-RGD radiolabelled with (90)Y or (177)Lu in a mouse model of αvβ3-expressing tumours.

Bozon-Petitprin A, Bacot S, Gauchez AS, Ahmadi M, Bourre JC, Marti-Batlle D, Perret P, Broisat A, Riou LM, Claron M, Boturyn D, Fagret D, Ghezzi C, Vuillez JP. Bozon-Petitprin A, et al. Among authors: fagret d. Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):252-63. doi: 10.1007/s00259-014-2891-7. Epub 2014 Aug 28. Eur J Nucl Med Mol Imaging. 2015. PMID: 25164771

8

Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?

Buffaz PD, Gauchez AS, Caravel JP, Vuillez JP, Cura C, Agnius-Delord C, Fagret D. Buffaz PD, et al. Among authors: fagret d. Eur J Nucl Med. 1999 Jan;26(1):8-11. doi: 10.1007/s002590050352. Eur J Nucl Med. 1999. PMID: 9933655

9

Cellular uptake of (99m)TcN-NOET in human leukaemic HL-60 cells is related to calcium channel activation and cell proliferation.

Guillermet S, Vuillez JP, Fontaine E, Caravel JP, Marti-Batlle D, Pasqualini R, Fagret D. Guillermet S, et al. Among authors: fagret d. Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):66-72. doi: 10.1007/s00259-005-1918-5. Epub 2005 Sep 29. Eur J Nucl Med Mol Imaging. 2006. PMID: 16193309

10

Chemical and biological evaluations of an (111)in-labeled RGD-peptide targeting integrin alpha(V) beta(3) in a preclinical tumor model.

Ahmadi M, Sancey L, Briat A, Riou L, Boturyn D, Dumy P, Fagret D, Ghezzi C, Vuillez JP. Ahmadi M, et al. Among authors: fagret d. Cancer Biother Radiopharm. 2008 Dec;23(6):691-700. doi: 10.1089/cbr.2008.0528. Cancer Biother Radiopharm. 2008. PMID: 19111043 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

124 results

Search Page

Filters